Get App

Merck cancer drug Keytruda succeeds in late-stage trial

Keytruda has already been approved to treat several forms of cancer including skin cancer and lung cancer.
  • Published On Nov 15, 2018 at 07:28 AM IST
Read by: 100 Industry Professionals
Reader Image Read by 100 Industry Professionals
U.S. drugmaker Merck & Co said on Wednesday its blockbuster cancer drug Keytruda met the main goal of a late-stage trial, of extending the lives of patients with cancers of the digestive tract.

Keytruda has already been approved to treat several forms of cancer including skin cancer and lung cancer.

The trial tested the drug in patients with a type of esophageal cancer who had already been given one other therapy.
  • Published On Nov 15, 2018 at 07:28 AM IST
Be the first one to comment.
Comment Now

COMMENTS

Comment Now Read Comment (1)

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles
Scan to download App